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Abstract
Background: Local control in malignant salivary gland tumours is dose dependent. High local control rates in
adenoid cystic carcinomas could be achieved by highly conformal radiotherapy techniques and particle (neutron/
carbon ion) therapy. Considering high doses are needed to achieve local control, all malignant salivary gland
tumours probably profit from the use of particle therapy, which in case of carbon ion treatment, has been shown
to be accompanied by only mild side-effects.
Methods/design: The COSMIC trial is a prospective, mono-centric, phase II trial evaluating toxicity (primary
endpoint: mucositis ≥ CTCAE°3) and efficacy (secondary endpoint: local control, disease-free survival) in the
combined treatment with IMRT and carbon ion boost in 54 patients with histologically proved (≥R1-resected,
inoperable or Pn+) salivary gland malignancies. Patients receive 24 GyE carbon ions (8 fractions) and IMRT (50 Gy
at 2.0 Gy/fraction).
Discussion: The primary objective of COSMIC is to evaluate toxicity and feasibility of the proposed treatment in all
salivary gland malignancies.
Trial Registration: Clinical trial identifier NCT 01154270
Background
Malignant salivary gland tumours are rare and a hetero-
genous group of tumours accounting for about 3-5% of
head and neck cancers. High-grade tumours such as
mucoepidermiod carcinoma (35%) and adenoid cystic
carcinoma (25%) are the most common histological sub-
types [1], characterised by a rather slow pattern of
growth, perineural spread and high propensity for hae-
matogenous metastases. So far, standard therapy of
high-grade salivary gland carcinoma consists of com-
plete surgical resection and adjuvant radiation in high-
risk situations (R+ or close margin, perineural spread,
neural infiltration, large tumours (T3/4), or nodal
metastases [2-4]. To achieve local control, radiation
doses of > 60 Gy or even 66 Gy (5) are recommended
[5,6], with apparently all tumour stages profiting from
postoperative radiotherapy [5,7-9].
Regarding radiation therapy, local control was also sig-
nificantly improved by the application of high-precision
techniques, dose-escalation and high-LET radiation
[9-13].
Intensity-modulated radiation therapy (IMRT) as well
as fractionated stereotactic RT could already improve
local control as compared to conventional RT techni-
ques achieving 3-year PFS rates of 38% [14].
So far, the highest local control rates at 75 - 100%
[11,13] were achieved by neutron radiation albeit at the
cost of significant late toxicity.
Dose escalation [12] though only in a small group of
patients, in treatment with heavy ions at 70.2 GyE (3 ×
3 . 9G y E / w k )o r6 4G y E( 4×4G y E / w k )w a ss h o w nt ob e
feasible and beneficial. Despite high doses per fraction,
no CTC °III late toxicities and very few °III acute reac-
tions occurred. Local control at 5 years was still 100%,
however, various histological subtypes of salivary gland
tumours were included in the trial. Pommier et al. [15]
treated 23 patients with adenoid cystic carcinoma with
protons at 75,9 GyE (median) in various fractionation
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ever, the authors noted several °III as well as one °V late
toxicity (temporal lobe necrosis). Douglas et al [11] pub-
lished a retrospective analysis of 159 patients with ade-
noid cystic carcinoma treated with neutrons (total dose:
19,2 Gy), but only reported somewhat disappointing local
control rates of 57% at 5 years accompanied with signifi-
cant late toxicity (14% > CTC °III). Results of the com-
bined IMRT-C12 treatment therefore compare
favourably [10] with only very mild treatment-related
side effects (°III late tox in only 1 patient) [16,17]. 54 Gy
IMRT (2 Gy/Fx) plus 18 GyE C12-boost (3 GyE/Fx)
yielded local control rates of about 78% at 4 years [10].
In view of the outcome and low toxicity profile,
photon IMRT plus C12-boost has been accepted as the
standard treatment and method of choice for adenoid
cystic carcinoma in Germany. Due to the possibility to
apply higher doses at so far mild side effects, charged-
particle therapy does promise improved results for all
types of malignant salivary gland cancers.
Therefore, this trial basically evaluates relative dose
escalation with simultaneous normal tissue sparing by
using a combination of C12-heavy ion therapy and
IMRT in all salivary gland malignancies including
mucoepidermoid carcinoma and adenoid cystic carci-
noma. Looking at other head and neck tumors i.e. squa-
mous cell carcinoma of the head and neck (SCCHN),
radiation therapy commonly causes pronounced mucosi-
tis. With therapy usually about 7 weeks duration and
mucositis, improvement of clinical symptoms can only
be expected at least 2-3 weeks post completion of ther-
apy. At the occurrence of mucositis CTC °III, pain, loss
of taste, and dysphagia causing reduced food/fluid intake
and weight loss can potentially cause treatment delays,
protraction of treatment and worse outcome. Therefore,
evaluation of this particular side effect was chosen as
the primary endpoint of the trial. Trial objectives hence
assess accompanying acute and late toxicity and focus-
ing on mucositis CTC °III. Secondary endpoints consist
of evaluation of efficacy (local control, disease-free survi-
val) and toxicity (other than mucositis).
Initial results of the pilot project at the GSI/Darmstadt
(treatment of skull base ACC) reported mucositis CTC °
III or higher in only 6% of cases, with a recent update
confirming these findings [18]. Assuming higher normal
tissue sparing by increase of the heavy-ion part of the
treatment, we would expect toxicity/mucositis rates
unchanged or even lower.
Methods/design
Study design
The COSMIC trial is a prospective, non-randomized
phase II feasibility trial evaluating acute mucositis ≥
CTCAE °III (v. 3.0) as the primary endpoint. Mucositis
CTCAE °III is defined as confluent ulcerations or pseu-
domembranes within the oral cavity and bleeding with
minor trauma leading to the inability of the patient to
adequately aliment or hydrate orally.
Study Characteristics
Combined IMRT and C12-heavy ion boost has pre-
viously been established as a treatment of choice in
skull-base adenoid cystic carcinoma. However, based on
the fact that local control seems to be dose-dependent,
all types of salivary gland malignancies in the head and
neck will probably benefit from high-LET radiation.
Therefore, the combination of IMRT (50 Gy in 2 Gy/
fraction) and C12-boost (24 GyE in 3 GyE/fraction) will
be tested as to toxicity profile and efficacy.
Study objectives
To evaluate feasibility and toxicity (with a focus on
mucositis CTCAE °III (v. 3.0)) and efficacy of the
treatment.
Incidence of mucositis ≥ CTCAE°III (v. 3.0) will be
assessed as the primary endpoint of the trial, local con-
trol, disease-free survival, toxicity (incl. mucositis
CTCAE °I-II and late toxicity at 3 years post RT)
Sample size/number of subjects
Incidence of mucositis CTCAE °III in the initial data
was 6% for adenoid cystic carcinoma mostly of the
skull base. 29 patients with adneoid cystic carcinoma
were treated with 54 Gy IMRT and 18 GyE carbon
ions, two of these patients (i.e. 6.9%) showed mucositis
CTCAE °III. Inclusion and exclusion criteria in COS-
MIC correspond to the initial patient selection; hence
incidence of toxicity should also roughly correspond.
Agreeing to an incidence of 6%, 49 patients have to be
treated in order to observe at least one patient with
mucositis CTCAE °III or higher with a probability of
95%. Assuming a drop-out rate of 10%, 54 patients
need to be recruited.
Patient selection
Inclusion criteria
￿ Histologically confirmed or surgically removed malig-
nant tumour of the salivary glands (head and neck)
￿ Inoperable tumour
￿ G2/3
￿ Macroscopic or microscopic residual tumour (R2/
R1) or
￿ ≥T3/T4 or
￿ perineural invasion (Pn+)
￿ written informed consent
￿ pts aged 18 - 80 years
￿ effective contraception for pts in childbearing age
(< 12 months post beginning of menopause)
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￿ Prior radio- or chemotherapy for tumours of the head
and neck
￿ Other previous malignancy within the past 5 years
except prior, adequately treated basal cell carcinoma of
the skin or pre-invasive carcinoma of the cervix
￿ Significant neurological or psychiatric condition
including dementia or seizures or other serious medical
condition prohibiting the patient’s participation in the
trial by judgement of the investigators
￿ Legal incapacity or limited legal capacity
￿ Positive serum/urine b-HCG/pregnancy
￿ Drug abuse
Radiotherapy
Immobilisation/planning examinations
Patients are immobilized using individual thermoplastic
head masks with thermoplastic shoulder fixation. Plan-
ning examinations consist of a planning CT scan (3 mm
slice thickness) with the patient positioned in the indivi-
dual fixation device and contrast-enhanced MRI for 3D
image correlation.
Target volumes/dose prescription
CTV1 (carbon ion boost) includes the macroscopic
tumour/prior tumour bed with special focus on the R1-
area as well as respective neural pathways to the base of
skull (cave: perineural invasion and skip lesions). For
tumours of the parotid gland, the whole former parotid
area is also included in the CTV1, if possible the man-
dibular joint is kept outside the CTV1. PTV1 consists of
a 3 mm margin around the CTV1 but does not extend
into critical organs at risk (i.e. brain stem, spinal cord).
We prescribe a dose of 24 GyE carbon ions in 3 GyE/
fraction (5 fractions per week) to the CTV1, we aim at
covering the CTV1 with the 95% prescription isodose.
Treatment is given at the HIT (Heidelberg ion therapy
centre) after inverse treatment planning in active beam
application (raster-scanning method). Daily image gui-
dance consists of orthogonal x-ray controls in treatment
position.
CTV2 includes CTV1 with safety margins along typi-
cal pathways of spread. Only ipsilateral nodal levels
(II and III) are includes, however, in case the primary
tumour is/was located at midline or crossing midline,
we cover bilateral nodal levels II and III. In case there is
a pathological lymph node involvement, additional nodal
level will be covered as indicated. CTV2 also encom-
passes the complete surgical operational area. The
CTV2 also takes account for set-up variations, hence
corresponds to the PTV2 (CTV2 = PTV2). Should the
primary tumour be located within the parotid gland,
also the parotid duct needs to be within the CTV2.
50 Gy IMRT (inversely planned step-and-shoot or
tomotherapy technique) in 25 fractions (5 fractions per
week) are prescribed to the CTV2 (coverage at least with
the 90% prescription isodose) taking into account doses
applied by daily image guidance with MV-cone-beam CT.
Supportive therapy
Patients do not routinely receive prophylactic feeding
tubes, however if they uncommonly experience signifi-
cant weight loss we will of course offer feeding tube
insertion or parenteral feeding.
Treatment schedule/follow-up
After obtaining written informed consent, patients are
included into the trial and receive their treatment plan-
ning investigations. Treatment usually starts with 8 frac-
tions carbon ion (8 × 3 GyE C12) therapy followed by
27/28 fractions of IMRT corresponding to a total dose
of approximately 74 GyE. Treatment duration is
approximately 6-7 weeks (figure 1).
First follow-up examination including diagnostic,
contrast-enhanced MRI will be carried out 6 weeks
post completion of radiation treatment. Further con-
trols including MRI are 3, 6, and 12 months thereafter,
in 6 monthly intervals until 2 years post RT, then in
yearly intervals. Abdominal ultrasound will be carried
out q6 months, chest-CT q12 months. At each follow-
up appointment, patients receive a symptom-oriented
clinical examination, also patients’ performance state
(Karnofsky-Index), therapy-associated side effects as
well as potential intercurrent therapy is recorded.
Patients are also encouraged to undergo regular
check-ups incl. full ENT clinical examinations in regular
intervals.
Proteomics and Genomics
For the proteomic examinations 30 mL venous blood
will be collected from each subject prior to RT, at day
29, day 44 or 45, and at the 1
st and 2
nd follow-up visit.
Thus, the overall volume of blood samples used for Pro-
teomic/Genomic investigations will be approximately
200 mL. Following parameters/pathways will be investi-
gated:
￿ In order to predict the efficacy of the therapy
blood will be collected during therapy and follow-up
to detect and correlate the levels of well known
tumour- and angiogenesis markers (VEGF, TGF-
Alpha, bFGF, IL8, k-ras, etc.) using Enzyme-Linked
Immunosorbent Assay (ELISA).
￿ Further, platelet protein content (i.e. tumor angio-
genesis growth factors and cytokines) will be ana-
lyzed using citrate blood samples and correlated
with serum- and plasma- protein results.
In order to perform the genomic analysis, patients’
blood samples are collected as indicated and RNA,
miRNA and DNA isolation will be performed. Based on
an established platform, linear RNA-amplification,
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oligo-arrays (transcriptome analysis) are planned. DNA
samples are used to identify potential chromosomal
aberrations or epigenetic alterations that might predict
treatment response. RNA and miRNA samples are
further analyzed by real time quantitative RT-PCR to
confirm microarray data and to test a subset of clinical
predictors.
The determinations of proteomic and genomic para-
meters will be carried out at the Department of Radiation
Oncology in Heidelberg. No further genetic investiga-
tions on the blood collected during the study will be
carried out.
Assessment of efficacy
Assessment of efficacy will be carried out by evaluation
of imaging studies (MRI) at each follow-up. If applicable
(in case of initial macroscopic tumour) tumour response
will be evaluated according to the RECIST-criteria (19).
Trial organization/coordination
The COSMIC trial has been designed by the Department
of Radiation Oncology, University of Heidelberg, and is
carried out at the Heidelberg Ion Therapy Centre (HIT).
It is an investigator-initiated trial; the Department of
Radiation Oncology is responsible for co-ordination,
overall trial management, registration (clinicaltrials.gov
Identifier: NCT 01154270), database management, qual-
ity assurance, monitoring, and reporting.
Investigators
Patients are recruited by the Department of Radiation
Oncology.
Adverse events
Adverse and serious adverse events are recorded using
NCI common toxicity criteria for adverse events
(CTCAEAE v. 3.0). Acute radiation effects are defined
as effects occurring within 90 days from beginning of
radiotherapy. Late effects are defined as effects observed
thereafter. Safety analysis is performed with respect to
frequency of serious adverse events and adverse events
stratified by organ system, severity, causality.
Regular completion of the trial
Patient accrual is completed with inclusion of the last
patient and should extend for approximately 2 years
from trial initiation. Regular trial participation for each
patient terminates 3 years post inclusion into the trial
or the patient’s death respectively.
Discontinuation of treatment
￿ Patient wish
￿ Medical condition necessitating treatment termina-
tion and withdrawal of the patient from the trial
￿ Pregnancy
￿ Lack of compliance
Premature termination of the trial
The trial can be prematurely closed or suspended by the
LKP in following cases:
￿ Medical or ethical reasons relevantly affecting the
risk-benefit relationship,
￿ Difficulties in recruitment of subjects suggest unjus-
tifiable prolongation of the study timeline,
￿ Previously unexpected adverse events (in respect of
their nature, severity, duration or outcome) occur with
unjustifiable frequency,
￿ Expected adverse events occur with an unexpectedly
high incidence,
￿ Relevant superiority of patients in one treatment
arm of a comparable clinical trial,
￿ Legal authorities’ decision
The Ethics Committee (EC) and the competent regu-
latory authorities will be informed about premature clo-
sure of the trial. Furthermore, the Ethics Committee(s)
and competent regulatory authorities themselves may
decide to stop or suspend the trial.
If the trial is closed prematurely, the trial material
such as completed, partially completed, and blank CRFs
will be returned to the coordinating investigator.
All involved investigators have to be informed imme-
diately about a cessation or suspension of the trial. The
decision is binding on all trial centers and investigators.
Ethics, informed consent, and safety
The final protocol was approved by the ethics commit-
tee of the University of Heidelberg Medical School
(S-263/2009). The trial complies with the Helsinki
Declaration in its recent German version, the Medical
Association’s professional code of conduct, principles of
Good Clinical Practice (GCP) guidelines and the Federal
Data Protection Act. It will be carried out in keeping
with local legal and regulatory requirements. It is also
Figure 1 trial flow-chart.
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tection authority (Bundesamt für Strahlenschutz: = BfS).
Medical confidentiality and Federal Data Protection Act
will be followed. Written informed consent is obtained
from each patient in oral and written form.
Discussion
Achieving local control in malignant salivary gland
tumour remains challenging. Progress has been made by
the introduction of novel radiotherapy techniques like
fractionated stereotactic RT and IMRT, however, parti-
cle therapy (neutron and carbon ion therapy) result in
the highest control rates in adenoid cystic carcinoma so
far. Compared to neutron RT, carbon ion treatment
comes at the cost of only mild side effects and is now
permanently available at a new dedicated particle ther-
apy facility (HIT). Considering the fact local control in
salivary gland tumours is dose dependent, we believe
treatment outcome can be improved for all malignant
salivary gland histologies without increasing side-effects
by a combination of IMRT (50 Gy) with a carbon ion
boost (24 GyE) not only in incompletely resected or
unresectable tumours but also in the R1-situation or
perineural infiltration. The COSMIC trial was designed
to address these issues in a prospective phase II trial. To
our knowledge this is the first phase II trail combining
particle therapy and IMRT.
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